The unique, high-affinity binding of cyanovirin-N (CV-N), a potent anti-human immunodeficiency virus (HIV) protein, to the HIV envelope glycoprotein gp120, was exploited to develop an HTS assay in an attempt to discover small-molecule mimetics of CV-N. A competition binding assay was developed using CV-N labeled with europium (Eu31). The labeling protocol did not significantly alter the gpl20 binding properties or the antiviral activity of CV-N. This report describes the assay development, validation, and results of screening a large library of aqueous and organic natural product extracts. The extracts were incubated with immobilized recombinant gpl20 in 96-well plates prior to the addition of Eu3+-labeled CV-N. Following a wash step, bound CV-N was measured by dissociation-enhanced time-resolved fluorometry of Eu3+. The assay proved to be robust, rapid, and reproducible, and was used to screen over 50,000 natural product extracts, and has resulted in the identification of several aqueous natural product extracts that inhibited CV-N-gp120 binding and also had anti-HIV activity.
References
1.
Piot, P. (1998). The science of AIDS: A tale of two worlds. Science280:1844-1845.
2.
Moore, J.P. (1995). HIV vaccines: Back to primary school. Nature376:115.
3.
Burton, D.R. (1997). A vaccine for HIV type 1: The antibody perspective. Proc. Natl. Acad. Sci. U.S.A.94:10018-10023.
4.
Heillman, C.A., Baltimore, D. (1998). HIV vaccines-where are we going?Nat. Med.4:532-534.
5.
Merson, M.H. (1993). Slowing the spread of HIV: Agenda for the 1990's. Science260:1266.
6.
Rosenberg, M.J., Holmes, K.K., and The World Health Organization Working Group on Virucides. (1993). Virucides in prevention of HIV infection. Sex. Transm. Dis.20:41-44.
7.
Lange, J.M., Karam, M., Piot, P. (1993). Boost for vaginal microbicides against HIV. Lancet342:1356.
8.
Elias, C.J., Coggins, C. (1996). Female-controlled methods to prevent sexual transmission of HIV. AIDS10:S43-S51.
9.
Boyd, M.R., Gustafson, K.R., McMahon, J.B., Shoemaker, R.H., O'Keefe, B.R., Mori, T., Gulakowski, R.J., Wu, L., Rivera, M.I., Laurencot, C.M., Currens, M.J., Cardellina, J.H. II, Buckheit, R.W., Nara, P.I., Pannell, L.K., Sowder, R.C. II, Henderson, L.E. (1997). Discovery of cyanovirin-N, a novel immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gpl20: Potential applications to microbicide development. Antimicrob. Agents Chemother.41:1521-1530
10.
Gustafson, K.R., Sowder, R.C. II, Henderson, L.E., Cardellina, J.H. II, McMahon, J.B., Rajamani, U., Pannell, L.K., Boyd, M.R. (1997). Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacteriumNostoc ellipsosporum. Biochem. Biophys. Res. Commun.238:223-228.
11.
Mori, T., Shoemaker, R.H., Gulakoswki, R.J., Krepps, B.L., McMahon, J.B., Gustafson, K.R., Pannell, L.K., Boyd, M.R. (1997). Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem. Biophys. Res. Commun.238:218-222.
12.
Picardo, M.I., Hughes, K.T. (1997). Scintillation proximity assays. In Devlin, J.P. (ed.), High Throughput Screening: The Discovery of Bioactive Substances, pp. 307-316. Marcel Dekker, Inc., New York.
13.
Rogers, M.V. (1997). Light on high throughput screening: Fluorescence-based assay technology. Drug Discov. Today2:156-160.
14.
Hemmila, I.A., Webb, S. (1997). Time-resolved fluorometry: An overview of the labels and core technologies for drug screening applications. Drug Discov. Today2:373-381.
15.
Inglese, J., Samama, P., Patel, S., Burbaum, J., Stroke, I., Appell, K. (1998). Chemokine receptor-ligand interactions measured using time-resolved fluorescence. Biochemistry37:2372-2377.
16.
Liu, J., Gallagher, M., Horlick, R.A., Robbins, A.K., Webb, M.L. (1998). A time-resolved fluorometric assay for galanin receptors. J. Biomol. Screen.3:199-206.
17.
Mellor, G.W., Burden, M.N., Preaudat, M., Joseph, Y., Cooksley, S.B., Ellis, J.H., Banks, M.N. (1998). Development of a CD28/CD86 (B7-2) binding assay for high throughput screening by homogeneous time-resolved fluorescence. J. Biomol. Screen.3:91-96.
18.
Kolb, A.J., Burke, J.W., Mathis, G. (1997). A homogeneous, time-resolved fluorescence method for drug discovery. In Devlin, J.P. (ed.), High Throughput Screening: The Discovery of Bioactive Substances, pp. 345-360. Marcel Dekker, Inc., New York.
19.
Hemmila, I., Dakubu, S., Mukkala, V.-M., Siitari, H., Lovgren, T. (1984). Europium as a label in time-resolved immunofluorometric assay. Anal. Biochem.137:335-343.
20.
Spencer, R.W. (1998). High-throughput screening of historic collections: Observations on file size, biological targets, and file diversity. Biotechnol. Bioeng.61:61-67.
21.
Mori, T., Gustafson, K.R., Pannell, L.K., Shoemaker, R.H., Wu, L., McMahon, J.B., Boyd, M.R. (1998). Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr. Purif12:151-158.
22.
Gulakowski, R.J., McMahon, J.B., Staley, P.G., Moran, R.A., Boyd, M.R. (1991). A semiautomated multiparameter assay for anti-HIV drug screening. J. Virol. Methods33:87-100.
23.
Parolis, L.A.S., Duus, J.O., Parolis, H., Meldal, M., Bock, K. (1996). The extracellular polysaccharide of Pichia (Hansenula) holstii NRRL Y-2448: The structure of the phosphomannan backbone. Carbohydr. Res.293:101-117.
24.
Parolis, L.A.S., Parolis, H., Kenne, L., Meldal, M., Bock, K. (1998). The extracellular polysaccharide of Pichia (Hansenula) holstii NRRL Y-2448: The phosphorylated side chains. Carbohydr. Res.309:77-87.
25.
Schmitz, F.J., Hollenbeak, K.H., Campbell D.C. (1978). Marine natural products: Halitoxin, toxic complex of several marine sponges of the genusHaliclona. J. Org. Chem.43:3916-3922.
26.
O'Keefe, B.R., Erim, T., Beutler, J.A., Cardellina, J.H. II, Gulakowski, R.J., Krepps, B.L., McMahon, J.B., Sowder, R.C., Johnson, D.G., Buckheit, R.W., Halliday, S.E., Boyd, M.R. (1998). Isolation and characterization of adociavirin, a novel HIV-inhibitory protein from the spongeAdocia sp. FEBS Lett.431:85-90.
27.
Zhang, J.H., Chung, T.D.Y., Oldenburg, K.R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen.4:67-73.
28.
Cardellina, J.H. II, Munro, M.H.G., Fuller, R.W., Manfredi, K.P., McKee, T.C., Tischler, M., Bokesch, H.R., Gustafson, K.R., Beutler, J.A., Boyd, M.R. (1993). A chemical screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural products extracts. J. Nat. Prod.56:1123-1129.
29.
Moore, J.P., Trkola, A., Dragic, T. (1997). Co-receptors for HIV-1 entry. Curr. Opin. Immunol.9:551.
30.
DeClercq, E. (1993). Antiviral agents: Characteristic activity spectrum depending on the molecular target with which they interact. Adv. Viral Res.42:1-55.
31.
Matsuzaki, K., Ikeda, H., Masuma, R., Tanaka, H., Omura, S. (1995). Isochromophilones I and II. Novel inhibitors against gpl2O-CD4 binding produced by Pencillium multicolor FO-2338 I: Screening, taxonomy, fermentation, isolation and biological activity. J. Ahtibiot. (Tokyo)48:703-707.
32.
Matsuzaki, K., Tahara, H., Inokoshi, J., Tanaka, H., Masuma, R., Omura, S. (1998). New brominated and halogen-less derivatives and structure-activity relationship of azaphilones inhibiting gp 120-CD4 binding. J. Antibiot. (Tokyo)51:1004-1011.
33.
Patil, A.D., Kumar, N.V., Kokke, W.C., Bean, M.F., Freyer, A.J., DeBrosse, C., Mai, S., Truneh, A., Faulkner, D.J., Carte, B., Breen, A.L., Hertzberg, R.P., Johnson, R.K., Westley, J.R., Potts, B.C.M. (1995). Novel alkaloids from the sponge Batzella sp.: Inhibitors of HIV gpl20-human CD4 binding. J. Org. Chem.60:1182-1188.
34.
Tanaka, H., Matsuzaki, K., Nakashima, H., Ogino, T., Matsumoto, A., Ikeda, H., Woodruff, H.B., Omura, S. (1997). Chloropeptins, new anti-HIV antibiotics inhibiting gpl2O-CD4 binding from Streptomyces sp.: I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. J. Antibiot. (Tokyo)50:58-65.
35.
Mori, T., Shoemaker, R.H., McMahon, J.B., Gulakowski, R.J., Gustafson, K.R., Boyd, M.R. (1997). Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Biochem. Biophys. Res. Commun.239:884-888.
36.
Esser, M.T., Mori, T., Mondor, I., Sattentau, Q.J., Dey, B., Berger, E.A., Boyd, M.R., Lifson, J.D. (1999). Cyanovirin-N binds to gpl20 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gpl20 or soluble CD4-induced conformational changes in gpl2O. J. Virol.73:4360-4371.
37.
Beutler, J.A., McKee, T.C., Fuller, R.W., Tischler, M., Cardellina, J.H. II, Snader, K.M., McCloud, T.G., Boyd, M.R. (1993). Frequent occurrence of HIV-inhibitory sulphated polysaccharides in marine invertebrates. Antiviral Chem. Chemother.4:167-172.
38.
Boyd, M.R. (1988). Strategies for the identification of new agents for the treatment of AIDS: A national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.), AIDS: Eitology, Diagnosis, Treatment and Prevention, pp. 305-319. Alan R. Liss, New York.
